Stuart J Collinson Net Worth

The estimated Net Worth of Stuart J Collinson is at least $25.3 Milion dollars as of 14 December 2006. Stuart Collinson owns over 50,019 units of Vertex Pharmaceuticals stock worth over $25,302,693 and over the last 21 years Stuart sold VRTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stuart Collinson VRTX stock SEC Form 4 insiders trading

Stuart has made over 7 trades of the Vertex Pharmaceuticals stock since 2006, according to the Form 4 filled with the SEC. Most recently Stuart exercised 50,019 units of VRTX stock worth $909,345 on 14 December 2006.

The largest trade Stuart's ever made was exercising 50,019 units of Vertex Pharmaceuticals stock on 14 December 2006 worth over $909,345. On average, Stuart trades about 8,847 units every 11 days since 2003. As of 14 December 2006 Stuart still owns at least 53,298 units of Vertex Pharmaceuticals stock.

You can see the complete history of Stuart Collinson stock trades at the bottom of the page.

What's Stuart Collinson's mailing address?

Stuart's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden oraz Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Complete history of Stuart Collinson stock trades at Soleno Therapeutics Inc i Vertex Pharmaceuticals

Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jeffrey Leiden,
  Executive Chairman of the Board
• Stuart Arbuckle,
  Executive Vice President, Chief Commercial Officer
• Reshma Kewalramani,
  President, Chief Executive Officer, Director
• Amit Sachdev,
  Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• David Altshuler,
  Executive Vice President - Global Research, Chief Scientific Officer
• Michael Parini,
  Executive Vice President, Chief Legal and Administrative Officer
• Dr. Reshma Kewalramani FASN, M.D.,
  CEO, Pres & Director
• Charles Wagner,
  Chief Financial Officer, Executive Vice President
• Paul Silva,
  Senior Vice President, Controller
• Dr. Jeffrey Marc Leiden M.D., Ph.D.,
  Exec. Chairman
• Stuart A. Arbuckle B.Sc.,
  Exec. VP & COO
• Dr. David M. Altshuler,
  Exec. VP of Global Research & Chief Scientific Officer
• Charles F. Wagner Jr.,
  Exec. VP & CFO
• Bruce Sachs,
  Co-Lead Independent Director
• Margaret McGlynn,
  Independent Director
• Terrence Kearney,
  Independent Director
• Sangeeta Bhatia,
  Independent Director
• Yuchun Lee,
  Independent Director
• William Young,
  Independent Director
• Alan Garber,
  Independent Director
• lloyd Carney,
  Independent Director
• Michael Partridge,
  Vice President - Investor Relations
• Diana McKenzie,
  Independent Director
• Nia Tatsis,
  Senior Vice President, Chief Regulatory Officer
• John Gray,
  Senior Vice President, Genetic Therapies
• Gerald Bruce,
  Executive Vice President, Commercial Operations
• Carmen Bozic,
  Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
• Joy Liu,
  Sr. VP & Gen. Counsel
• Damian W. Wilmot Esq.,
  Sr. VP, Chief Risk and Compliance Officer
• Mike Tirozzi,
  SVP and Chief Information & Data Officer
• Kristen Ambrose,
  Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
• Joshua S Boger,
  Chairman & CEO
• Elaine Ullian,
  Director
• Ian F Smith,
  SVP & CFO
• Jeffrey Chodakewitz,
  SVP GMDA, CMO
• Thomas Graney,
  Chief Financial Officer
• Michel Lagarde,
  Director
• Wayne Joseph Riley,
  Director
• Peter Mueller,
  CSO & SVP Drug Discovery
• Thomas Connolly,
  SVP, Human Resources
• Kenneth L Horton,
  EVP & Chief Legal Officer
• Megan E Pace,
  SVP, Corp. Communications
• Christiana Stamoulis,
  SVP, Corp Strategy & Bus Devlp
• Matthew Emmens,
  Director
• Lisa Kelly,
  SVP, Human Resources
• Dennis L Winger,
  Director
• Eugene Cordes,
  Director
• Nancy Wysenski,
  EVP & Chief Commercial Officer
• David T Howton,
  SVP
• Kenneth S Boger,
  SVP & General Counsel
• Kurt Graves,
  EVP, Chief Commercial Officer
• John J Alam,
  SVP, Drug Eval. & Appr.
• Stuart J Collinson,
  Director
• Charles A Sanders,
  Director
• Roger W Brimblecombe,
  Director
• Freda C Lewis Hall,
  EVP, Medicines Development
• Eve Elizabeth Slater,
  Director
• Richard C Garrison,
  SVP, Organizational Developmen
• Johanna Messina Power,
  Controller
• Victor A Hartmann,
  EVP, Strategic & Corp. Devlp.
• Eric Brandt,
  Director
• Lynne H Brum,
  VP, Corp. Comm.&Financial Plan
• Paul A Negulescu,
  VP, Research
• John F Niblack,
  Director
• Iain P M Buchanan,
  VP, European Operations
• Vicki L Sato,
  President
• N Anthony Coles,
  SVP, Comm. Ops.
• Bastiano Sanna,
  EVP, Cell & Genetic Therapies
• Joy Liu,
  SVP, General Counsel
• Kristen Ambrose,
  SVP & Chief Accounting Officer
• Suketu Upadhyay,
  Director
• Jonathan Biller,
  EVP and Chief Legal Officer
• Nancy Thornberry,
  Director
• Edward Morrow Iii Atkinson,
  EVP, Chief Technical Ops. Off.
• Jennifer Schneider,
  Director